ABOUT EXSIGHT CATALYST
Decades of clinical, operational, and venture capital experience for ophthalmic innovation companies and their industry partners
From Investment to Advisory
ExSight Ventures Founded
2014
Five funds, multiple exits, $1B+ in follow-on capital
2014 - 2024
ExSight Catalyst Spins Out
2025
A decade of conviction.
ExSight Ventures was founded in 2014 to pioneer specialized early-stage ophthalmology venture capital. The thesis was simple: deep domain expertise and ecosystem access create unique value beyond capital deployment.
Along the way, the firm's expertise was sought out by industry and innovators independent of capital investment. ExSight Catalyst spun out to formalize that practice.
"We see what others miss — on both sides of the table."
FOR INVESTORS
Traditional life science VCs concentrate in oversized funds with long cycles, high burn, and limited shots. Investors combining capital efficiency with deep scientific knowledge remain scarce.
FOR FOUNDERS
Exceptional founder-led startups get lost between funding tiers. Each innovation follows a different clinical and regulatory path that's difficult to navigate alone.
THE MULTIPLIER EFFECT
Invest in $9.5B. Access $407B+.
Ophthalmology is the diagnostic gateway to the world's most expensive chronic conditions. A small investment market opens an enormous adjacent one.
WHERE YOU INVEST
$9.5B
Annual Ophthalmology
Market Size
THE ENTRY POINT
TOTAL ADJACENT MARKET ACCESS
What you access: Annual market size of adjacent specialties
$173.7B
$144.5B
$89.3B
A single ophthalmic innovation can serve as the diagnostic entry point to detecting or treating the world's most expensive chronic conditions across multiple specialties.
Neurology
Retinal thinning predicts cognitive decline and MS progression.
Cardiology
Retinal vessel analysis identifies hypertension & stroke risk early.
Nephrology
Ocular biomarkers stage Chronic Kidney Disease non-invasively.
$407B+
OUR TEAM’S AFFILIATIONS
